News24/09/2026
Prime Medicine reports FDA clearance for PM647 clinical study
Prime Medicine, Inc. →Prime Medicine reported FDA clearance of its investigational new drug application for PM647 in alpha-1 antitrypsin deficiency. The clearance enables clinical study in the United States. PM647 remains investigational, and the announcement is not marketing approval.